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To the Editor: We read with interest the review article by Mühlhauser and Meyer [1] in the June 2013 issue. However, we would like to highlight that incomplete information was given within Table 1 , which summarises existing reviews of type 2 diabetes guidelines, including those by Bennett et al [2] and the German Institute for Quality and Efficiency in Health Care [3] .
The table correctly states that in the published review by Bennett and colleagues [2] the Scottish Intercollegiate Guidelines Network 2010 guideline (SIGN 116) [4] was not included. However, we would like to highlight that the authors later provided a substantial erratum in which SIGN 116 was included [5] . This was in response to a letter from some of the present authors [6] .
In the erratum, SIGN 116 scored 97.6% for rigour of development and 100% for editorial independence, making it one of the highest quality international diabetes guidelines available.
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